# Bristol-Myers Squibb Company (BMY) — Q2-2023 Earnings Results

**Report date:** 2023-07-27 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q2-2023

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Misses on EPS — Stock Down 4.23%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.75 | N/A | -12.10% |

### Management Commentary

**Tone:** Defensive

Management acknowledged the difficulties in meeting earnings expectations. They emphasized the importance of their product pipeline while recognizing current market pressures.

**Key quotes:**

> We are focused on navigating current market challenges.

> Our pipeline remains strong, but we face headwinds in the near term.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a significant miss on EPS, which contributed to a 4.23% decline in stock price. The company did not provide revenue figures or future guidance, leaving investors uncertain about its short-term performance. Management's cautious tone suggests ongoing challenges ahead, particularly in navigating market conditions.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q2-2023_